Eli Lil­ly claims suc­cess in a new JAK in­di­ca­tion: hair loss

Over the last decade, drug­mak­ers have proven JAK in­hibitors can treat a smat­ter­ing of im­mune-re­lat­ed dis­eases rang­ing from rheuma­toid arthri­tis to Covid-19. Now Eli Lil­ly has pulled out a new one.

Lil­ly and its biotech part­ner In­cyte an­nounced Wednes­day that their JAK in­hibitor baric­i­tinib ef­fec­tive­ly re­grew pa­tients’ hair in a Phase III tri­al for alope­cia area­ta, an au­toim­mune con­di­tion that can cause sud­den, se­vere and patchy hair loss. Lil­ly didn’t break down the re­sults from the 546-pa­tient tri­al, but the pri­ma­ry end­point was im­prove­ment on a stan­dard score for alope­cia symp­toms.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.